Shots:

• The company has reported the expansion of P-III PREVENT-19 pivotal trial to evaluate the efficacy- safety- and immunogenicity of NVX-CoV2373 vs PBO in ~3-000 adolescents aged 12-17yrs. against COVID 19 across 75 sites in the US
• Patients will receive two doses of either NVX-CoV2373 or PBO given 21 days apart and participants will be monitored for safety for up to 2 yrs. following the final dose
• In a recent UK trial- Novavax's vaccine was 96.4% effective against the original strain- 86.3% effective against the B.1.1.7/501Y.V1 variant and 89.7% overall

  Ref: PRNewswire | Image: Novavax